Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Share-based Compensation (2021 - 2023)

Cullinan Therapeutics (CGEM) has 3 years of Share-based Compensation data on record, last reported at $7.5 million in Q4 2023.

  • For Q4 2023, Share-based Compensation changed 0.08% year-over-year to $7.5 million; the TTM value through Dec 2023 reached $30.4 million, up 8.87%, while the annual FY2025 figure was $36.0 million, 4.72% down from the prior year.
  • Share-based Compensation reached $7.5 million in Q4 2023 per CGEM's latest filing, down from $7.7 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $12.1 million in Q4 2021 and bottomed at $3.5 million in Q1 2021.
  • Average Share-based Compensation over 3 years is $6.9 million, with a median of $7.4 million recorded in 2022.
  • The widest YoY moves for Share-based Compensation: up 106.67% in 2022, down 38.14% in 2022.
  • A 3-year view of Share-based Compensation shows it stood at $12.1 million in 2021, then tumbled by 38.14% to $7.5 million in 2022, then grew by 0.08% to $7.5 million in 2023.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $7.5 million in Q4 2023, $7.7 million in Q3 2023, and $7.9 million in Q2 2023.